Yardley, D. A., Coleman, R., Conte, P., Cortes, J., Brufsky, A., Shtivelband, M., . . . Harbeck, N. (2018). nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: Results from the tnAcity trial. Ann Oncol.
Style de citation ChicagoYardley, D A., et al. "Nab-Paclitaxel Plus Carboplatin or Gemcitabine Versus Gemcitabine Plus Carboplatin As First-line Treatment of Patients With Triple-negative Metastatic Breast Cancer: Results From the TnAcity Trial." Ann Oncol 2018.
Style de citation MLAYardley, D A., et al. "Nab-Paclitaxel Plus Carboplatin or Gemcitabine Versus Gemcitabine Plus Carboplatin As First-line Treatment of Patients With Triple-negative Metastatic Breast Cancer: Results From the TnAcity Trial." Ann Oncol 2018.